Imed Follow-up: Does Theranica's Valuation Hold Beyond the Series D Round
Theranica's roughly $35 million Series D and revenue growth to $25.8 million give Imed a stronger anchor than a routine private-market mark, but Imed's carrying value still rests on PWERM, preferred-share economics, and an assumed liquidity event within 2 to 3 years. The mark looks defensible inside the capital structure, but it is not yet a clean standalone value.
What This Follow-up Is Isolating
The main article argued that Imed's cash position looks better, but the portfolio's value still sits on three private marks. This follow-up isolates Theranica alone, because by year-end 2025 it is already the largest holding in the portfolio at a fair value of $1.747 million, and it is also the holding where the valuation mechanics are disclosed deeply enough to inspect the capital stack itself.
The question here is not whether Theranica is a real company or whether the Series D round happened. That part is clear. The real question is whether Imed's mark in Theranica still holds once the natural excitement around a roughly $35 million financing round is stripped out. The short answer is yes, but only up to a point. Imed's carrying value looks reasonable inside Theranica's capital structure and inside the preferred-share rights that Imed owns. It still does not look like a value that has fully detached from the round itself, because the model explicitly rests on the Series D financing, on a liquidity event within 2 to 3 years, and on a payout waterfall shaped by liquidation preferences.
What matters immediately:
- Series D did not create a sharp rerating of Imed's old mark. It mostly added new cash and bought time.
- The $1.747 million carrying value is higher than the naive roughly $1.53 million calculation from 1.13% of $135.1 million, because Imed owns D and C-1 preferred shares rather than common stock.
- The argument over a 20% versus 22% discount rate moves tens of thousands of dollars, not the core thesis. The real risk is whether a liquidity event actually arrives by mid-2028.
- The model gets most of its value from a high-M&A scenario, not from an IPO and not from already proven profitability.
What Series D Actually Bought
Start with the number that is easiest to miss. At the end of 2024, Theranica was marked at $1.384 million inside Imed. During 2025, Imed injected another roughly $458 thousand into Theranica through the Series D round. By the end of 2025, the fair value stands at $1.747 million, and Note 5(d) explicitly says that Theranica's value decreased by roughly $95 thousand during 2025, even after that follow-on investment.
In practice, that means Series D did not retroactively reprice Imed's old position upward. It mainly kept Imed in the round and added a more senior layer of shares. Anyone reading the $1.747 million mark as if Theranica simply jumped in value because it raised money is missing the point. The round stabilized the mark, but it did not by itself create a broad economic uplift on the legacy position.
That is not necessarily negative. In a portfolio like Imed's, a follow-on check is often meant to prevent excessive dilution, improve the position in the preference stack, and buy another couple of years of runway. That is the right reading here.
Why Imed's Mark Is Higher Than a Simple Pro Rata Math
Theranica's valuation sets equity value at roughly $135.1 million. Imed's post-round holding stands at roughly 1.13% on a fully diluted basis. A simple multiplication would get you to about $1.53 million. But the valuation gives Imed $1.7477 million. That gap is not a mistake. It comes from the capital structure.
In Theranica's allocation table, Series D shares are worth $2.98 per share, Series C shares $2.86, Series C-1 shares $2.72, Series B shares $2.32, while common shares and employee options are valued at $1.40 per share. Imed holds exactly two layers above common: 153,796 Series D shares and 474,261 Series C-1 shares.
| Share class | Imed share count | Value per share | Value attributed to Imed |
|---|---|---|---|
| D | 153,796 | $2.98 | $458.5 thousand |
| C-1 | 474,261 | $2.72 | $1.289 million |
| Total | 628,057 | $1.748 million |
This matters because it changes how the mark should be read. If the story were simply that Imed owns 1.13% of a private company valued at $135 million, it would be easy to dismiss the carrying value as just another round-based pro rata mark. In reality, the mark also reflects how that $135.1 million is allocated across different security classes. Imed's value does not rest only on company value. It also rests on sitting above common stock in the payout waterfall.
In that sense, the mark does hold beyond the simplest pro rata reading. It holds inside the capital-stack math of the round.
But the Model Is Still Heavily Dependent on the Round
This is the point where the analysis has to stop and tighten up. The fact that capital structure gives Imed a better cushion does not make the mark independent of Series D. Quite the opposite. The valuation file explicitly says Theranica's equity value was inferred from the December 2025 Series D preferred financing of roughly $35 million. The PWERM comes after that. In other words, the round is not just a market datapoint. It is the anchor.
The scenario table leaves very little room for fantasy. Most of the weighted value comes from a high-M&A outcome.
| Scenario | Expected timing | Probability | Equity value in scenario | Contribution to weighted value |
|---|---|---|---|---|
| IPO | December 31, 2027 | 10% | $300 million | $20.8 million |
| M&A - High | June 30, 2028 | 45% | $350 million | $99.8 million |
| M&A - Default Recovery | December 30, 2028 | 25% | $100 million | $14.5 million |
| Dissolution | December 30, 2028 | 20% | $0 | $0 |
In plain English, the model is not saying Theranica has already proven a $300 million or $350 million value today. It is saying something narrower: if there is a liquidity event within 2 to 3 years, if most of the probability weight sits on a successful sale, and if the preferred-share waterfall is respected, then current value comes out at $135.1 million at the company level and $1.7477 million at Imed's level.
That is a much narrower conclusion. It is also a much more honest one.
Where the Real Argument Sits
It is easy to get stuck on the 20% discount rate, but that is not where the center of gravity sits. The sensitivity table shows that moving to 18% or 22% changes Imed's Theranica value to a range of about $1.803 million to $1.696 million. The move from the midpoint is roughly $50 thousand in each direction. That is not trivial, but it is not what decides the thesis.
The real argument sits somewhere else: whether a liquidity event actually happens within the assumed 2 to 3 years, and whether it is strong enough to justify the high-M&A scenario that carries almost $100 million of the weighted value.
That matters even more because Theranica's capital structure includes 8% annual liquidation preference accruals for Series D first, then Series C and C-1, then Series B, then Series A, and then Seed. Only after that does the residual value flow to common and selected preferred classes, with a 3.5x cap for some of the preferred layers. A delay in liquidity is therefore not only a discounting problem. It is also a question of preference accretion and possible erosion of the lower layers of the stack.
For Imed, that cuts both ways. It helps because Imed owns D and C-1, which sit above common. But it also reminds readers that the value Imed reports is not a simple common-equity mark. It is the product of a structured rights table that still needs a real-world exit to be fully tested.
There Is Also an Operating Anchor, and It Is Not Small
If this were only about preferred-share mechanics, the mark would be much easier to dismiss. But that is not the whole story. Theranica's business section also shows real operating progress. The company has one commercial product, Nerivio. In 2025 it launched a new version, reached insurance coverage for more than 130 million Americans, and grew revenue from roughly $14 million in 2024 to roughly $25.8 million in 2025. Management says the company met its 2025 goals, and that 2026 is about further expanding coverage and improving actual reimbursement capture from covered prescriptions.
Those numbers matter because they show Theranica is not living on a slide deck. There is a real product, real revenue, and fast growth. It would be too aggressive to say Imed's mark is just a modeling exercise.
But the same section also says the company is still not profitable and still relies mainly on equity financing. So yes, there is real business progress, but it has not yet replaced the need for outside capital. In that sense, Series D is both validation and oxygen. As long as both are true at the same time, it is hard to argue that the valuation fully stands on its own feet.
Conclusion
Theranica's value inside Imed holds better than it may look at first glance, but for a very specific reason. It holds inside the capital structure, not outside it. The D and C-1 shares that Imed owns are worth more than common stock inside the allocation table, so the $1.747 million carrying value is not just a mechanical copy of fully diluted ownership. That is the strong side of the mark.
The weak side is that the mark still sits deep inside the Series D financing, the PWERM, and a liquidity event pushed out to 2027 or 2028. Theranica's operating progress is real and respectable, with $25.8 million of revenue and broader insurance coverage, but the company is still not profitable and still relies on external capital. So if the question is whether Imed is simply inflating a number with no basis, the answer is no. If the question is whether Theranica has already proven a valuation that stands fully on its own, without the round and without the preference stack, the answer is still no.
What has to happen next for this mark to move from "reasonable calculation" to "strong proof" is simpler than the model itself: more commercial progress, better reimbursement capture, and above all a real liquidity event that tests the capital structure in the market rather than only inside the model.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.